Opdivo (nivolumab) has an elimination half-life of about 25 to 27 days, meaning it takes roughly four to five months for the drug itself to clear from your bloodstream after your final infusion. But the biological effects of Opdivo can persist much longer than the drug’s measurable presence, which is an important distinction if you’re stopping treatment or planning a medical procedure.
How Long the Drug Stays in Your Blood
The FDA reports nivolumab’s mean elimination half-life at about 25 to 27 days. A half-life is the time it takes for your body to clear half of the remaining drug. After one half-life (roughly a month), half the drug is gone. After two half-lives (about two months), 75% is gone. Pharmacologists generally consider a drug functionally cleared after about five half-lives, which for Opdivo works out to approximately 125 to 135 days, or four to four and a half months.
That said, “functionally cleared” means the concentration has dropped below a level that’s typically measurable or meaningful in blood tests. Trace amounts may linger slightly longer. If you’re on the 480 mg every four weeks schedule rather than the 240 mg every two weeks schedule, your peak blood levels are about 45% higher after each infusion, but the half-life is the same. The drug clears at the same rate regardless of dose.
Biological Effects Last Much Longer
Here’s where it gets more nuanced. Opdivo works by binding to PD-1 receptors on your immune cells, essentially removing a brake that was preventing those cells from attacking cancer. Even after the drug itself is gone from your blood, those receptors can remain occupied for months.
Research tracking PD-1 receptor occupancy after patients stopped nivolumab found that it took about 32 weeks (roughly 8 months) for receptor occupancy to drop by just 50%, and nearly 49 weeks (close to a year) to drop by 70%. This means your immune system continues operating in an “activated” state well beyond the point where the drug is detectable in your bloodstream. This extended immune activation is part of why Opdivo can produce durable responses in some cancers, but it’s also why side effects can appear long after treatment ends.
Delayed Side Effects After Stopping
Because Opdivo’s immune-activating effects persist so long, new immune-related side effects can surface months after your last infusion. Researchers have documented what they call “delayed immune-related events,” defined as new side effects appearing 90 or more days after stopping treatment. In published case series, the median time to these delayed events was six months after the last dose, with some occurring as late as 28 months out.
These can include inflammation affecting the thyroid, liver, skin, joints, or other organs. The key takeaway: if you develop unexplained symptoms in the months following your last Opdivo infusion, the drug’s lingering immune effects should be considered as a possible cause, even if the infusions feel like distant history.
What Affects How Quickly You Clear It
Not everyone clears Opdivo at the same rate. The half-life figure of 25 to 27 days is an average, and individual variation is substantial. The FDA’s population analysis noted a coefficient of variation around 77 to 101%, meaning clearance times differ widely from person to person. Three factors have the strongest influence:
- Body surface area: People with a body surface area above 2.2 square meters (generally larger individuals) tend to clear the drug more than 20% faster.
- Sex: Women clear nivolumab about 22% more slowly than men, meaning the drug may stay in their systems somewhat longer.
- Albumin levels: Low serum albumin (a blood protein often reduced in people who are malnourished or have liver disease) is associated with faster drug clearance.
Kidney and liver function, which heavily influence the clearance of most traditional drugs, have less impact on nivolumab. This is because Opdivo is a large antibody protein that gets broken down by the body’s general protein recycling processes rather than being filtered through the kidneys or metabolized by the liver.
Washout Periods for Procedures
If you’re stopping Opdivo before a surgery or another medical treatment, your care team will factor in a washout period. This varies depending on the procedure. For liver transplant patients who received checkpoint inhibitors including nivolumab, research has identified a minimum safe washout of about 42 days (roughly 1.5 half-lives) as the shortest interval associated with significantly better outcomes and lower rejection risk.
For other procedures or treatments, the required washout may differ. The important thing to understand is that “cleared from the blood” and “no longer affecting the immune system” are two very different timelines with Opdivo. The drug may be undetectable in your blood within four to five months, but its immune effects can persist for a year or more. Any decisions about timing of surgeries, vaccines, or new treatments should account for that longer biological window.
Steady State and Cumulative Exposure
If you’re currently receiving Opdivo, the drug reaches steady-state concentration (the point where the amount entering your body with each infusion roughly equals the amount being cleared) at about 12 weeks of treatment. After that point, drug levels stabilize into a predictable pattern of peaks after each infusion and troughs just before the next one. When you stop treatment, clearance begins from whatever your steady-state level is, following the same half-life timeline of roughly 25 to 27 days per halving.
For the 480 mg every four weeks schedule, trough levels are about 16% lower than the 240 mg every two weeks schedule, while peak levels run about 45% higher. The overall average exposure is similar between the two schedules, and the total clearance time after stopping is comparable regardless of which dosing schedule you were on.